Enteric-coated aspirin may be inferior to chewable aspirin after TKA
Click Here to Manage Email Alerts
Key takeaways:
- Chewable aspirin showed lower venous thromboembolism rates after total knee arthroplasty vs. enteric-coated aspirin.
- Both aspirin types showed similar complication rates for total hip arthroplasty.
GRAPEVINE, Texas — Results presented here showed low-dose enteric-coated aspirin was inferior to uncoated chewable aspirin for venous thromboembolism prophylaxis in total knee arthroplasty, but not total hip arthroplasty.
However, enteric-coated aspirin and uncoated chewable aspirin showed similar gastrointestinal complication rates in both TKA and THA.
Yale A. Fillingham, MD, and colleagues retrospectively compared data from patients who underwent primary THA or TKA between 2017 to 2021 and received either uncoated chewable low-dose aspirin (n=4,844) or enteric-coated low-dose aspirin (n=4,388).
“In terms of baseline characteristics, they were largely similar between the two groups with the exception that the enteric-coated aspirin [group] had a slightly higher BMI, as well as slightly older age,” Fillingham said in his presentation at the American Association of Hip and Knee Surgeons Annual Meeting.
When THA and TKA procedures were combined, Fillingham said the uncoated chewable aspirin group and the enteric-coated aspirin group had no significant differences in venous thromboembolism (VTE) and gastrointestinal (GI) complication rates. He added patients who underwent THA also had no significant differences in VTE and GI complication rates between the two groups. However, patients who underwent TKA had a significantly lower incidence for VTE in the uncoated chewable aspirin group, but no differences in GI complication rates, according to Fillingham.
“When it does come to GI complication rates, there does not appear to be a difference between the two formulations and, as such, it may be reasonable for us to consider a transition from enteric-coated to uncoated chewable low-dose aspirin for our VTE prophylaxis following elective primary hip and knee [procedures],” Fillingham said.
Collapse
D’Amore T, et al. Paper 29. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Nov. 2-5, 2023; Grapevine, Texas.
Click Here to Manage Email Alerts